SCHEMBL6105953

SCHEMBL6105953

CC(C)N1CCC(C(=O)Nc2cccc(Cl)c2C(=O)Nc2ccc(Cl)cn2)CC1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ F10 P00742 8/20 0.72
▸ RAB9A P51151 2/20 0.49
▸ MAPK1 P28482 1/20 0.49
▸ F2 P00734 1/20 0.47
▸ MAPT P10636 2/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ BRD4 O60885 1/20 0.46
▸ KCNH2 Q12809 1/20 0.45
▸ ACKR3 P25106 1/20 0.45
▸ LMNA P02545 1/20 0.44
▸ TP53 P04637 1/20 0.44
▸ GAA P10253 1/20 0.44
▸ TSHR P16473 1/20 0.44
▸ PTBP1 P26599 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ WNT1 P04628 1/20 0.44
▸ GSK3B P49841 1/20 0.44
▸ DYRK1A Q13627 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6109270 0.92 F10 (0.68) F10RAB9AMAPK1F2MAPT
Hydrochloric Acid SCHEMBL6107369 0.91 F10 (0.67) F10RAB9AMAPK1F2MAPT
Hydrochloric Acid SCHEMBL6107825 0.86 F10 (0.81) F10RAB9ALMNATP53GAA
Hydrochloric Acid SCHEMBL6772450 0.86 F10 (0.70) F10RAB9AMAPK1F2KCNH2
Hydrochloric Acid SCHEMBL6107312 0.85 F10 (0.74) F10RAB9AMAPK1F2ALDH1A1
SCHEMBL6108341 0.83 F10 (1.00) F10KCNH2
SCHEMBL6108359 0.83 F10 (0.85) F10RAB9AMAPK1F2KCNH2
SCHEMBL6106348 0.83 F10 (0.51) F10RAB9AMAPK1MAPTALDH1A1
Hydrochloric Acid SCHEMBL6108144 0.83 F10 (0.98) F10KCNH2
Hydrochloric Acid SCHEMBL6772686 0.82 F10 (0.79) F10RAB9AMAPK1F2KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030171403-A1 Blockade of voltage dependent sodium channels UNIVERSITY COLLEGE LONDON (GB) 2003-09-11 — — US claimed
US-7129245-B2 Anticoagulants which act selectively on factor Xa; fast acting; oral; do not interfere with lysis of blood clots ELI LILLY AND COMPANY (US) 2006-10-31 — — US disclosed
US-7009056-B2 Blockade of voltage dependent sodium channels UNIVERSITY COLLEGE LONDON (GB) 2006-03-07 — — US disclosed
US-20050282862-A1 Aromatic amides BEIGHT DOUGLAS W 2005-12-22 — — US disclosed
EP-1140903-B1 AROMATIC AMIDES LILLY CO ELI (US) 2004-08-04 — — EP disclosed
US-6759414-B2 ANTICOAGULANTS WHICH ACT SELECTIVELY ON FACTOR XA; FAST ACTING; ORAL; DO NOT INTERFERE WITH LYSIS OF BLOOD CLOTS ELI LILLY AND COMPANY 2004-07-06 — — US disclosed
US-20040029874-A1 Aromatic amides BEIGHT DOUGLAS WADE (US) 2004-02-12 — — US disclosed
US-6635657-B1 Pyridine derivatives; anticoagulants ELI LILLY AND COMPANY 2003-10-21 — — US disclosed
US-20030171403-A1 Blockade of voltage dependent sodium channels UNIVERSITY COLLEGE LONDON (GB) 2003-09-11 — — US disclosed
EP-1140903-A1 AROMATIC AMIDES ELI LILLY AND COMPANY (US) 2001-10-10 — — EP disclosed
WO-2000039118-A1 AROMATIC AMIDES ELI LILLY AND COMPANY (US) 2000-07-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171403-A1 Blockade of voltage dependent sodium channels CACNA1F, SCNN1B, CACNA1B F10 1987/4885RAB9A 1482/4885MAPK1 803/4885
US-20040029874-A1 Aromatic amides F11, F12, F5 F10 12/4885RAB9A 2097/4885MAPK1 1009/4885
US-20050282862-A1 Aromatic amides F11, F12, F5 F10 12/4885RAB9A 2097/4885MAPK1 1009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback